Royalty Pharma EVP Urist Marshall Sells 4,126 Shares

What Happened

• Urist Marshall, EVP, Research & Investments at Royalty Pharma (RPRX), sold 4,126 Class A ordinary shares on 2026-09-28 at $57.88 per share, for a total proceeds of $238,813. The transaction is reported as an open-market or private sale.

Key Details

• Transaction date and price: 2026-09-28 — 4,126 shares at $57.88 each (total $238,813).
• Shares owned after transaction: Not specified in the provided filing for Class A ordinary shares.
• Footnote: The sale was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 26, 2026.
• Filing date/timeliness: Form 4 filed 2026-09-30 (two days after the trade), which is generally within the Form 4 reporting window.
• Additional holdings disclosed: The reporting person and family vehicles hold limited partnership interests exchangeable into 2,444,120 Class A shares and Class E ordinary shares of RPH exchangeable into 1,356,528 Class A shares; Class E shares are subject to vesting conditions.

Context

• The sale was executed under a 10b5-1 plan, which typically means the trade followed a pre-set instruction rather than signaling a discretionary decision based on inside information. Sales are common for liquidity or diversification and do not by themselves indicate a change in company outlook.